C
Cardiff Oncology D
D
CRDF
3.34000
USD
-0.40
(-10.70%)
قبل الجلسة
حجم التداول
483
الربح لكل سهم
-1
العائد الربحي
-
P/E
-2
حجم السوق
222,196,352
الأخبار المقالات
العنوان: Cardiff Oncology
القطاع: Healthcare
الصناعة: Biotechnology
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.